Motilal Oswal Wealth Management Research Desk has recommended RR Kable as a large-cap pick with a current market price of ₹2,602 and a target price of ₹2,960, offering a potential upside of 14%. According to the research report, RR Kable delivered a strong Q1FY27 performance with revenue growing 54% YoY to ₹31.7 billion and EBITDA nearly doubling to ₹2.8 billion, driven by robust C&W volume growth and healthy execution in the FMEG segment. The C&W segment delivered ~17% YoY volume growth, outperforming the industry's estimated 10-12%, while management reiterated confidence in achieving 10.5% C&W margins by FY28 and sustainable FMEG break-even in FY27. Bajaj Finance is another large-cap recommendation with a current price of ₹1,135 and target of ₹1,300, offering 14.5% upside potential. The company reported strong Q1FY27 performance with NII growing 23% YoY and PAT rising 28% YoY, supported by broad-based loan growth and resilient margins.
KFin Technologies has been recommended as a mid-cap pick with a current market price of ₹936 and target price of ₹1,150, providing 23% upside potential. As reported by Motilal Oswal, the company delivered steady Q1FY27 performance with operating revenue rising 30% YoY, driven by 182% YoY growth in international solutions following the Ascent acquisition. RR Kable has also been upgraded to BUY with improved profitability and margin expansion expected to drive earnings growth. The company delivered 7% YoY EBITDA growth with a healthy 34.2% EBITDA margin, while PAT of ₹752m came in 7% above estimates due to better operating efficiency. Management has guided for 18-20% revenue growth in FY27, supported by cost optimization initiatives and a robust pipeline across businesses.
Sun Pharma has been recommended as a mid-cap pick with a current price of ₹1,989.4 and target price of ₹2,310, offering 16% upside potential. According to Motilal Osla Financial Services (MOFSL), the company delivered robust Q1FY27 performance that met analyst expectations, signaling future growth. The company is expanding its specialty and innovative medicines portfolio significantly, with semaglutide serving as a key growth lever beyond India, where the company has secured approvals for generic semaglutide injections for Type-2 diabetes in South Africa and Brazil. The Organon acquisition is expected to complete by March 2027 quarter, which could expand Sun Pharma's global scale and product portfolio. Key milestones over the next 12-18 months include a USFDA decision on Ilumya for psoriatic arthritis in October 2026, topline phase-II data for GL0034 in Type-2 diabetes during the second half of 2027, and regulatory filings for dermatology and oncology assets.
Syrma SGS Technology has been identified as a small-cap opportunity with a current price of ₹1,383 and target of ₹1,770, offering 28% upside potential. According to the research, the company delivered robust Q1FY27 performance with revenue surging 68% YoY to ₹15.9 billion, driven by strong growth across Auto (+78% YoY), Consumer (+68% YoY), and IT/Railways/Healthcare segments. Emcure Pharma is another small-cap recommendation with a current price of ₹1,982 and target of ₹2,260, providing 14% upside potential. The company is expected to deliver CAGR of 14%/20%/28% in revenue/EBITDA/PAT over FY26-28, supported by strong growth across regulated international markets and a diversified domestic franchise.
TCI Express has been highlighted by Motilal Oswal as delivering a subdued quarter amid challenging demand conditions in the logistics sector. However, the brokerage believes the company remains well-placed to benefit from an eventual recovery in industrial activity and e-commerce-led logistics demand. The firm expects TCI Express to benefit from recovery in industrial and e-commerce sectors and has maintained its view on the stock while updating earnings estimates and target price. These latest recommendations come as Motilal Oswal reviewed Q1 earnings of select companies including TCI Express, Biocon, and Deepak Nitrite, revising target prices and estimates while reiterating ratings based on business performance, margin trends and growth outlook.
